14 Aug 2026

CRC Research Update — August 14, 2026

Creator: The CRC Digest
Published: 2026-08-14T11:31:52Z

Today's colorectal cancer research highlights

1 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

RESEARCH
KRAS Mutations and Liver Metastases Predict Worse Outcomes in Third-Line Metastatic CRC
A pooled analysis of placebo-controlled trials from the ARCAD CRC Database found that KRAS mutations and liver metastases are independently associated with poorer prognosis in patients receiving third-line therapy for metastatic colorectal cancer. (Clinical Colorectal Cancer)
TREATMENT
Sotorasib Plus Panitumumab Compared to Standard Therapy in Chemorefractory Metastatic CRC
A matching-adjusted indirect comparison evaluated sotorasib plus panitumumab versus trifluridine/tipiracil plus bevacizumab in chemorefractory metastatic colorectal cancer. (Clinical Colorectal Cancer)
SCREENING
Anorectal Visits Offer Missed Screening Opportunity for Adults Under 50
Among 776 patients seen for benign anorectal conditions, only 60.5% of adults aged 45-49 had undergone colonoscopy in the prior 10 years, highlighting a missed opportunity to promote screening during routine visits. (American Journal of Surgery)
TREATMENT
Rare DPYD Variant Linked to Severe Fluoropyrimidine Toxicity
A 50-year-old colorectal cancer patient developed life-threatening grade 3-4 toxicities after adjuvant XELOX; sequencing identified a rare intronic DPYD variant (c.2766+3A>T) that causes exon 21 skipping and profound DPD deficiency, which was missed by routine genotyping. (British Journal of Clinical Pharmacology)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Younger CRC Patients Face Distinct Quality of Life Challenges
A qualitative study comparing early-onset colorectal cancer patients to older patients found that young people with colorectal cancer experience worse psychological wellbeing, including marked emotional distress and prominent levels of anxiety. (Quality of Life Research)

Stay informed, stay hopeful — research continues to move forward.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest